Outcomes in COVID-19 siltuximab studies

All studies   Mortality   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -64% 1 149 Improvement, Studies, Patients Relative Risk Mortality -64% 1 149 RCTs -64% 1 149 Late -64% 1 149 Siltuximab for COVID-19 c19early.org November 2025 Favorssiltuximab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] death 15/75 9/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Late treatment -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk All studies -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk 1 siltuximab COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Effect extraction pre-specified(most serious outcome) Favors siltuximab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] 15/75 9/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Late treatment -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk All studies -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk 1 siltuximab COVID-19 mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Favors siltuximab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] death 15/75 9/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Late treatment -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk All studies -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk 1 siltuximab COVID-19 serious outcome c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Effect extraction pre-specified(most serious outcome) Favors siltuximab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] death 15/75 9/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Late treatment -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk All studies -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk 1 siltuximab COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Effect extraction pre-specified(most serious outcome) Favors siltuximab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] 15/75 9/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Late treatment -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk All studies -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk 1 siltuximab COVID-19 RCT mortality result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Favors siltuximab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] death 15/75 9/74 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Late treatment -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk All studies -64% 1.64 [0.77-3.52] 15/75 9/74 64% higher risk 1 siltuximab COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.2 Effect extraction pre-specified(most serious outcome) Favors siltuximab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COV-AID Declercq (RCT) -64% 1.64 [0.77-3.52] death 15/75 9/74 Improvement, RR [CI] Treatment Control Siltuximab COVID-19 outcomes c19early.org November 2025 Favors siltuximab Favors control